Heart Disease, Technology / 07.03.2024
Remote Patient Monitoring for Effective Heart Disease Management
Heart disease remains a leading cause of morbidity and mortality worldwide. Despite advances in medical technology and treatment modalities, managing heart disease remains challenging. This is particularly true in remote or underserved areas with limited access to specialized healthcare.
However, remote patient monitoring (RPM) has transformed the landscape of cardiac care, offering innovative solutions for proactive management and early intervention. The market for remote patient monitoring was projected to be valued at $14.0 billion in 2023, according to PR Newswire. By 2028, it is anticipated to increase to $41.7 billion.
This article explores the significance of remote patient monitoring in effectively managing heart disease and its evolving role in enhancing patient outcomes.
According to the AACR Cancer Progress Report, cancer survivors have significantly improved from 50 years ago. It constituted only 1.4 percent of the US population earlier, but they have increased considerably. The number of cancer survivors is estimated to grow to
The importance of external support systems becomes even more crucial as the number of children with disabilities and other developmental disorders continues to surge. This trend is apparent in academic settings, where there is a rising number of students with disabilities. According to the Pew Research Center, nearly
Dr. Magruder[/caption]
Matthew Magruder, MD PGY3
Orthopaedic Residency Program
Department of Orthopaedic Surgery and Rehabilitation
Maimonides Medical Center
MedicalResearch.com: What is the background for this study?
Response: The prevalence of obesity and diabetes mellitus has reached epidemic proportions. Approximately 37.3 million people in the United States, accounting for 11.3% of the total population, have diabetes, and 100.1 million, or 41.9%, of all US citizens are obese. Furthermore, these numbers are only projected to increase in the coming decades. This is an issue for orthopaedic surgeons because diabetes and obesity have consistently been demonstrated to be risk factors for complications following total joint replacements, especially total hip replacements. Therefore, we are in desperate need of new and more effective tools in mitigating the risk of poor outcomes in our joint replacement patients.
Semaglutide, and other GLP-1 agonists, are potentially a new tool that can be used to help decrease the risks following joint replacement surgery. Initially a medication to treat diabetes, semaglutide has recently been approved by the FDA to treat obesity as well, as randomized controlled trials have consistently demonstrated significant weight loss with minimal side effects. The purpose of our study was to see what effect the use of semaglutide had on total hip arthroplasty patient outcomes.
Dr. Akefe[/caption]
Isaac O Akefe DVM, PhD
Clem Jones Centre for Ageing Dementia Research
Queensland Brain Institute
The University of Queensland St Lucia
Academy for Medical Education, Medical School
Brisbane QLD Australia
MedicalResearch.com: What is the background for this study?
Response: The brain is the body’s fattiest organ, with fatty compounds called lipids making up 60% of its weight. Fatty acids are the building blocks of a class of lipids called phospholipids.
In our study, we first showed that levels of saturated fatty acids increase in the brain during neuronal communication and long-term memory formation, but we didn’t know what was causing these changes.
It is your lifestyle that determines your blood pressure levels. Your nutritional intake and the level of activity have a significant part as well.
Wilson N. Merrell
Ph.D. Student
Dr. Li Li[/caption]
Li Li, M.D., Ph.D., M.P.H
Walter M. Seward Professor
Chair of Family Medicine
Director of population health
University of Virginia School of Medicine
Editor-in-chief of The BMJ Family Medicine
Dr. Li joined the U.S. Preventive Services Task Force in January 2021
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Speech and language delays and disorders can be challenging for children and their families and can lead to difficulties with reading and writing as children grow up.
The Task Force looked at the evidence on screening for speech and language delays and, unfortunately, there is not enough evidence to tell us whether or not it is helpful to screen all children 5 years old and younger for speech and language delays and disorders.
